CTOs on the Move


 
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.abcuro.com
  • 90 Bridge Street Suite 100
    Newton, AB USA 02458
  • Phone: 617.714.9759

Executives

Name Title Contact Details

Funding

Abcuro raised $42M on 01/07/2021

Similar Companies

Tmunity

Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)

Ossium Health

Ossium is building the world`s first bone marrow bank to treat blood cancers, improve organ transplantation, and repair damage from radiation.

SiChuan Sanherb Biotech

SiChuan Sanherb Biotech is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pervasis Therapeutics Inc

Pervasis Therapeutics Inc is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mixture Sciences Inc

Mixture Sciences Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.